Christer Nordstedt
Chairman at WNTRESEARCH AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nicholas Waters | M | 62 | 11 years | |
| Gunnar Olof Olsson | M | 71 | 7 years | |
| Erik Viktor Siewertz | M | 53 | 11 years | |
| Tommy Evert Andersson | M | 68 | 17 years | |
| Hans-Peter Albert Ostler | M | 53 |
Oblique Therapeutics AB
 Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
| Kicki Johansson | M | 66 | 6 years | |
| Catharina Gustafsson Wallich | F | 60 | 2 years | |
| Outi Vaarala | M | 62 | 5 years | |
| Daniel Johnsson | M | 60 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | 1 years |
| Gudrun Anstrén | F | 69 | 6 years | |
| Hilpi Rautelin | M | 63 | 7 years | |
| Clas Sonesson | M | 63 | 11 years | |
| Peter Jan Sture Ström | M | 72 | 9 years | |
| Mats Lindskog | M | - |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | 1 years |
| Tuukka Hirvonen | M | - | 5 years | |
| Rein Piir | M | 66 | 8 years | |
| Carola Elisabet Lemne | M | 66 | 5 years | |
| Ari Tapio Lehtoranta | M | 61 | 7 years | |
| Peder Svensson | M | 62 | 11 years | |
| Lennart Erik Jonas Sjögren | M | 58 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
| Veronica Wallin | F | 38 | 1 years | |
| Susanna Waters | M | 58 | - | |
| Joakim Tedroff | M | 63 | 8 years | |
| Claes Tomas Post | M | 74 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
| Marianne Dicander Alexandersson | F | 65 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
| Janna Sand-Dejmek | F | - | - | |
| Anders Tidfors | M | - | 4 years | |
| Dennis Bang Henriksen | M | 62 | 8 years | |
| Heikki Joensuu | M | 68 | 7 years | |
| Klaus Christensen | M | 56 | 5 years | |
| Per Norlén | M | 54 | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hannu Tapani Syrjänen | M | 73 | 10 years | |
| Maria Jalmelid | F | 45 | 5 years | |
| François Martelet | M | 64 | 2 years | |
| An van Es-Johansson | M | 64 | 1 years | |
| Pia Kristiina Kalsta | F | 54 | - | |
| Jan C. Fagerberg | M | 62 |
Karolinska Institutet
| 3 years |
| Elina Heliö | F | 52 | 14 years | |
| Xiao Jun Xu | M | - |
Karolinska Institutet
| 3 years |
| Desiree Luthman | M | 65 |
Karolinska Institutet
| 3 years |
| Pernilla Sandwall | F | 61 | - | |
| Richard Stuart Godfrey | M | 58 | 1 years | |
| Anders Rabbe | M | 54 | 2 years | |
| Heidi Ahti | F | - | - | |
| Mats Norman | M | 61 |
Karolinska Institutet
| 4 years |
| Reijo Juhani Salonen | M | 68 | 11 years | |
| Jukka Arvo Ylppö | M | 69 | 10 years | |
| Lilli Riikonen | F | - | 2 years | |
| Gisela Marie Sitbon | M | 66 |
Karolinska Institutet
| 3 years |
| Christer Möller | M | 65 |
Karolinska Institutet
| 3 years |
| Lars Gösta Jonsson | M | 83 |
Karolinska Institutet
| 19 years |
| Lars Gunnar Lannfelt | M | 75 |
Karolinska Institutet
| 3 years |
| Karl Härfstrand | M | 66 |
Karolinska Institutet
| 9 years |
| Eugen Steiner | M | 70 |
Karolinska Institutet
| 15 years |
| Carl Harald Janson | M | 66 |
Karolinska Institutet
| 3 years |
| Jonas Bergh | M | 70 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 44 | 78.57% |
| Finland | 12 | 21.43% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christer Nordstedt
- Personal Network
